Press Releases

News Release - June 13, 2018
AMO Pharma Receives FDA Orphan Drug Designation for AMO-04 in Treatment of Rett Syndrome


News Release - May 7, 2018
AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome


News Release - March 15, 2018
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1


News Release - October 18, 2017
AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting


In the Media

FDA Grants Orphan Drug Designation to New Treatment for Rett Syndrome - June 15, 2018

https://www.raredr.com/news/fda-grants-orphan-drug-designation-to-new-treatment-for-rett-syndrome

 

Phelan-McDermid Syndrome Treatment Commences Clinical Trial Recruitment - May 11, 2018

http://www.raredr.com/news/phelanmcdermid-syndrome-treatment-commences-clinical-trial-recruitment

 

AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome - May 8, 2018

http://www.checkorphan.org/news/amo-pharma-announces-initiation-of-clinical-trial-conducted-by-mount-sinai-to-study-amo-01-in-treatment-of-phelan-mcdermid-syndrome

 

AMO Pharma Advancing Ultra-Rare Program on Back of Phase IIb Data - April 10, 2018

http://www.bioworld.com/content/amo-pharma-advancing-ultra-rare-program-back-phase-iib-data/

 


Early Clinical Trials of AMO-02 Show Promise in Congenital and Childhood Myotonic Dystrophy Type 1 - March 23, 2018

https://medicalresearch.com/author-interviews/early-clinical-trials-of-amo-02-show-promise-in-congenital-and-childhood-myotonic-dystrophy-type-1/40741/

Companies pair up to take Rett Syndrome program into clinic - July 20, 2017

https://www.thepharmaletter.com/article/companies-pair-up-to-take-rett-syndrome-program-into-clinic/

 

News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact - July 20, 2017

http://www.fiercebiotech.com/biotech/news-note-trevena-cmo-exit-amo-deal-kala-ipo-alivecor-mayo-pact

 

FDA Gives Fast Track Status to Potential Therapy for Congenital Myotonic Dystrophy - June 1, 2017

https://musculardystrophynews.com/2017/06/01/amo-02-congenital-myotonic-dystrophy-treatment-gains-fda-fast-track/

 

AMO Pharma receives FDA Fast Track Status - May 30, 2017

http://european-biotechnology.com/up-to-date/latest-news/news/amo-pharma-receives-fda-fast-track-status.html

 

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - May 30, 2017

http://labiotech.eu/amo-pharma-amo-02-myotonic-dystrophy/

 

AMO Pharma Addresses Rare Childhood Disease - May 22, 2017

https://www.clinicalleader.com/doc/amo-pharma-addresses-rare-childhood-disease-0001

 

Ranedis and AMO Partner to Develop HDAC Inhibitor for Rare Genetic Diseases - March 14, 2017

http://www.genengnews.com/gen-news-highlights/ranedis-and-amo-partner-to-develop-hdac-inhibitor-for-rare-genetic-diseases/81254020

 

AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal - March 14, 2017

https://www.thepharmaletter.com/article/amo-pharma-and-ranedis-target-rare-genetic-diseases-in-rnd-001-deal

 

Wayne-Based AMO Pharma Raises $25 Million - October 1, 2015

https://patch.com/pennsylvania/te/wayne-based-amo-pharma-raises-25-million

 

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma - October 1, 2015

http://labiotech.eu/neil-woodford-amo-pharma-25m/


Subscribe
Stay updated about AMO! Enter your information here to receive updates about AMO Pharma via email:



Unsubscribe
To unsubscribe from all AMO Pharma communications, please click here.